

Novel HPC-Ibuprofen Conjugates: Synthesis, Characterization, Thermal Analysis and Degradation Kinetics

¹ Muhammad Ajaz Hussain*, ¹ Bilal Ahmad Lodhi, ¹ Khawar Abbas,
¹ Rizwan Nasir Paracha, ² Muahmmad Raza Shah and ¹ Muhammad Adaf Arsalan
¹ Department of Chemistry, University of Sargodha, Sargodha 40100, Pakistan.
² International Center for Chemical and Biological Sciences,
University of Karachi, Karachi 75270, Pakistan
majaz172@yahoo.com*

(Received on 15th March 2013, accepted in revised form 13th June 2013)

Summary: Naturally occurring hydrophilic polysaccharides are nowadays attracting the vigil eye of researchers working in areas of drug design and development. Amongst them, hydrophilic biopolymer hydroxypropylcellulose (HPC) is of particular interest. Its unique geometry allows the attachment of drug molecules with higher covalent loading as the hydroxyls are projected outside the polymer chains. The HPC-Ibuprofen conjugates as macromolecular prodrugs were therefore synthesized employing homogenous and one pot reaction methodology using *p*-toluenesulfonyl chloride. Present strategy appeared effective to synthesize conjugates with high yield (77-81%). Acid-base titration after saponification and ¹H-NMR spectroscopic analyses have revealed high degree of drug substitution (DS 0.88-1.40) on to HPC. Uni-modal absorptions were observed in gel permeation chromatograms which indicated no significant degradation of polymer. Macromolecular prodrugs with different DS of ibuprofen were synthesized, purified, characterized and found soluble in organic solvents. From thermogravimetric analysis, initial, maximum and final degradation temperatures of the conjugates were calculated and compared for relative thermal stability. Thermal degradation kinetics was also studied and results have indicated that degradation of conjugates follows about first order kinetics as calculated by Kissinger model. The energy of activation was also found moderate 92.38, 99.34 and 87.34 kJ/mol as calculated using Friedman, Broido and Chang models. It was found that these novel prodrugs of ibuprofen were thermally stable therefore these may have potential pharmaceutical applications.

Keywords: Hydroxypropylcellulose, Ibuprofen, Macromolecular prodrugs, Polysaccharides, Thermal analysis

Introduction

Ibuprofen (*(RS)*-2-(4-(2-methylpropyl) phenyl) propanoic acid) belongs to propanoic acid derivatives class of non-steroidal anti-inflammatory drugs (NSAIDs). Ibuprofen is a famous drug is being used worldwide due to its efficacy and patient compliance. However, prolong use of ibuprofen drug is causative of nausea, stomach pain, vomiting and GIT disorders [1, 2]. Hence, macromolecular prodrugs (HPC-ibuprofen conjugates) can minimize side effects of ibuprofen because such conjugates are acid resistant, bypass stomach and release drug in intestine.

Hydroxypropylcellulose (HPC) is an important polysaccharide being used in prodrug design and applications. It has a number of valuable properties in this regard, such as, hydrophilicity, neutral nature, biocompatibility, biodegradability and cost-effectiveness. Therefore, HPC has perhaps all properties which are prerequisite for any drug carrier [3-6]. Several studies have shown the potential of hydroxypropylmethylcellulose (HPMC) and HPC in pharmaceutical and biomedical sciences [7-12].

Additionally, some related cellulose ether derivative based macromolecular prodrug design showed nanoassemblies in solution along with improved pharmacokinetic profile and thermal stability [13, 14]. A well-designed pathway for water-soluble polysaccharide based prodrugs [15, 16] is the covalent linkage of the drug onto the polymer by ester linkage using soft reaction conditions. *p*-toluenesulfonyl chloride is an efficient and widely used reagent for such conversions and better than the conventional reagents like acid chlorides and acid anhydrides [17, 18] which may impart toxic side products and impurities in prodrugs.

In this study, we report on homogenous and one pot synthesis of novel macromolecular prodrugs of ibuprofen using a hydrophilic polysaccharide HPC. Effects of increasing molar ratio on to the DS are also being reported. Further, we are focused on thermogravimetric analysis and degradation kinetics of newly synthesized prodrugs to access their thermal behavior.

*To whom all correspondence should be addressed.




Fig. 3: The ¹H-NMR (400 MHz, DMSO-*d*₆, NS 16) spectrum of HPC-Ibuprofen conjugate **3** (DS 1.40).

The HPC-Ibuprofen conjugates **1-3** were carefully characterized by ¹H-NMR (400 MHz, DMSO-*d*₆) spectroscopy. From spectra it is therefore inferred that ibuprofen was attached to HPC as the aromatic Hs are found at δ 7.10-7.65, 7.08-7.65 and 7.13-7.64 ppm for samples **1-3**, respectively. Protons of HPC polymer repeating unit were detectable at δ 3.14-4.40, 3.15-4.39 and 3.17-4.37 ppm for sample **1**, **2** and **3**, respectively. Fig. 3 depicts a representative ¹H-NMR spectrum of sample **3** (DS 1.40). The CH₃ signals of HP moiety onto HPC polymer appeared at δ 1.03 ppm. The -CH₂ and -CH protons of HP moiety were found overlapped with repeating unit of HPC. The protons of both methyl groups (H-10) were seen at 0.84 ppm while another methyl group of drug (H-11) appeared at 1.33 ppm. The CH (H-12) in drug was recognized by its typical septet signal centered at 1.77 ppm. The CH₂ of drug (H-13) was assigned for 2.40 ppm. The ¹H-NMR spectroscopic analysis therefore showed successful synthesis of HPC-Ibuprofen conjugates due to presence of all related signals. DS was calculated from ¹H-NMR spectra by the comparison of signal intensities and found to be 0.88, 1.02 and 1.40 for sample **1-3**, respectively. DS obtained from ¹H-NMR spectra were found comparable with DS values calculated using acid base titration after saponification and results are gathered in Table-1.

Gel permeation chromatography (GPC) was carried out for the assessment of polymer degradation during reaction. From GPC results, it is inferred that present synthesis strategy and reaction conditions did not cause significant degradation of the polymer

chains in HPC-Ibuprofen conjugates as uni-modal absorptions were only seen in spectra. For instance, GPC spectrum of HPC-Ibuprofen conjugate **2** is shown in Fig. 4.




Fig. 4: The GPC analysis of HPC-Ibuprofen conjugate **2** (DS 1.02) indicating uni-modal absorption.

Shelf-life of prodrugs or drugs can be increased by acquiring stability of drug in macromolecular prodrug conjugates. Polysaccharide based prodrugs generally attain higher thermal stability in case of NSAIDs conjugates [4]. Therefore, thermal analysis of pure drug ibuprofen, HPC polymer and HPC-Ibuprofen conjugates were recorded. The overlay TG and DTG curves of ibuprofen, HPC and HPC-Ibuprofen conjugate **3** are depicted in Fig. 5 and 6, respectively while thermal degradation data obtained from these graphs are summarized in Table-2.




Fig. 5: Overlay TG curves of HPC, ibuprofen and HPC-ibuprofen conjugate **3** (DS 1.40).




Fig. 6: Overlay DTG curves showing comparative degradation patterns of ibuprofen, HPC and their conjugate **3** (DS 1.40).

Table-2: Results of Thermogravimetric analysis for HPC, ibuprofen and HPC-Ibuprofen conjugate **3** (DS 1.40).

| Sample | Tdi | Tdm | Tdf | Weight loss (%) at Tdf | Char yield Wt (%) |
|--------------------|-----|-----|-----|------------------------|-------------------|
| HPC | 240 | 365 | 396 | 99.85 | 0.05 % at 563°C |
| Ibuprofen | 135 | 233 | 245 | 95.39 | 1.06 % at 259°C |
| Conjugate 3 | 160 | 246 | 292 | 95.73 | 1.53 % at 400°C |

Tdi, Tdm, Tdf = Initial, maximum, final thermal decomposition temperatures in °C.

Table-3: Comparative kinetic parameters calculated using different kinetic models for ibuprofen and HPC-Ibuprofen conjugate **3** (DS 1.40).

| Sample | Method | R ² | n | m | Ea (KJ/mol) | lnZ | Z (s ⁻¹) |
|----------------------------------|-----------|----------------|---|--------|-------------|-------|----------------------|
| Ibuprofen | Friedman | 0.999 | | -9158 | 76.14 | 23.14 | 1.86×10 ⁸ |
| | Broido | 0.999 | | -13604 | 113.11 | 27.11 | 9.89×10 ⁹ |
| | Chang | 0.999 | | -10822 | 89.98 | 26.88 | 7.86×10 ⁹ |
| | Kissinger | | 1 | | | | |
| HPC-Ibuprofen conjugate 3 | Friedman | 0.997 | | -11111 | 92.38 | 18.57 | 1.9×10 ⁶ |
| | Broido | 0.998 | | -11948 | 99.34 | 21.89 | 5.3×10 ⁷ |
| | Chang | 0.999 | | -10505 | 87.34 | 23.4 | 2.4×10 ⁸ |
| | Kissinger | | 1 | | | | |

R² = correlation factor; n = order of reaction; M = slope, Ea = Energy of activation; Z = shape index.

Single step degradation of ibuprofen was observed that started at 135°C (Tdi) and ended at 245°C (Tdf) while maximum decomposition (Tdm) was observed at 233°C. Although analysis was performed up to 800°C but TG and DTG curves got parallel at temperature 277°C and no further change in mass was observed in the thermogram of pure ibuprofen. Thermal analysis revealed that Tdm for ibuprofen, HPC and HPC-Ibuprofen conjugates **3** were found at 233, 365 and 246°C, respectively. It was concluded from data that ibuprofen got extra thermal stability after prodrug formation (sample **3**). Prodrug of ibuprofen becomes 13°C more stable than pure drug regarding Tdm. It is also important to note that degradation of HPC-ibuprofen conjugates start 25°C (Tdi 160°C) later than pure ibuprofen drug (Tdi 135°C). Nevertheless, thermal results have indicated that thermally more stable prodrugs of ibuprofen based on HPC were successfully fabricated showing potential for higher shelf life due to extra thermal stability.

Friedman, Chang, Broido and Kissinger models were used to calculate kinetic parameters of thermal degradation of ibuprofen, HPC and HPC-Ibuprofen conjugate **3**, e.g., energy of activation (Ea), correlation factor (R²), slope (m), order of reactions (n) and frequency factor (Z). Plots of Friedman, Chang and Broido were drawn using TG and DTG curves. Kinetic parameters obtained from these graphs are summarized in Table-3. The Ea values of HPC-Ibuprofen conjugate **3** were found comparable, i.e., 92.38, 99.34 and 87.34 kJ/mol as calculated from Friedman, Broido and Chang models, respectively for first and major degradation step 1. In second step, less than 5% degradation was observed that may correspond to furfural formation from polysaccharide (HPC) material. Comparable Ea values of HPC-Ibuprofen conjugates and drug are indicative of stability of ibuprofen in HPC-Ibuprofen conjugates. The n was calculated by Kissinger model and it was found that degradation of HPC-Ibuprofen conjugate follows first order kinetics.

Experimental

Reagents and Chemicals

Hydroxypropylcellulose (MS 3.46, 60% HP moieties; Nanjing Yeshun Industry & International Trading Co. Ltd, Jiangsu China-Mainland) was dried at 110°C for 5 h to remove moisture contents. Analytical reagent grade organic solvents and other chemicals (Fluka) were used as obtained. The HCl and NaOH ampule (1 mol/L) of Merck were used for acid-base titration. Ibuprofen (gifted by Candid Pharmaceuticals, Sialkot, Pakistan) was of US pharmacopoeia (USP) standard.

Measurements

The FTIR (KBr) spectra were measured on IR-Prestige 21 (Shimadzu, Japan) using KBr pellet technique where pellets were dried under vacuum before taking spectra in order to remove traces of moisture or entrapped solvent if any. The ¹H-NMR (400 MHz) spectra of the HPC-Ibuprofen conjugates were acquired in DMSO-*d*₆ and all spectra were recorded with 16 numbers of scans. Agilent Technology 1200 (Germany) series equipment was used for GPC analyses of HPC-Ibuprofen conjugates 1-3. The instrument was equipped with pump (PU-980), refractive index detector (RI 930), degasser (DG -980-50) and UV detector (UV-975 at 254 nm). The polymer standards columns were used for the size exclusion chromatography using DMF solvent at a flow rate of 0.5-1.0 cm³/min at 40-45°C. The GPC equipment was calibrated with polystyrene standards. Thermal analyses of the HPC-Ibuprofen conjugates were carried out using TA Instrument equipped with a thermo-balance (SDT Q600 USA). To record simultaneous thermal analysis, temperature was varied at the rate of 10°C/min from ambient to 800°C. The thermal data were analyzed by MS Excel[®] 2010 and Universal Analysis 2000 software v 4.2E.

Dissolution of the HPC

For typical preparation HPC (2 g) was dissolved in DMAc (30 mL) by heating for 30 min at 80°C to obtain clear solution.

Synthesis of HPC-Ibuprofen Conjugates; a Typical Example (Sample 3)

Ibuprofen (3.40 g, 16.5 mmol) was added to the solution of HPC (2 g, 5.5 mmol) in DMAc containing imidazole (2.25 g, 33.0 mmol). *In situ* activating agent, *p*-toluenesulfonyl chloride (3.16 g,

16.5 mmol) was added in parts to the reaction mixture. Reaction was preceded at 80°C for 24 h under nitrogen. The reaction mixture was precipitated in diethyl ether (300 mL) and washed three times to remove un-reacted drug and by products. The precipitates of HPC-Ibuprofen conjugates were dried at 40°C for 24 h.

DS: 1.33 by acid base titration after saponification and 1.40 by ¹H-NMR spectroscopy; Yield: 2.90 g (81%); FTIR (KBr): 3090 ν(OH), 1730 ν(CO_{Ester}), 1445 ν(CH₂) cm⁻¹; ¹H-NMR (DMSO-*d*₆, δ ppm): 1.03 (H-9), 0.84 (H-10), 1.33 (H-11), 1.77 (H-12), 2.40 (H-13), 3.17-3.90 (HPC repeating unit-H-2-8), 4.37 (H-1), 1.03 (H-9), 7.13-7.64 (aromatic-Hs). Same procedure was adopted for all of samples and analytical data of rest of the products is given below.

Analytical Data for Synthesis of HPC-Ibuprofen Conjugates, (Sample 1)

DS: 0.83 by acid base titration after saponification and 0.88 by ¹H-NMR spectroscopy; Yield: 2.3 g (77%). FTIR (KBr): 3039 ν(OH), 1738 ν(CO_{Ester}), 1452 ν(CH₂) cm⁻¹; ¹H-NMR (DMSO-*d*₆, δ ppm): 1.03 (H-9), 0.85 (H-10), 1.32 (H-11), 1.76 (H-12), 2.42 (H-13), 3.14-4.40 (other AGU-H-1-5), 7.10-7.65 (aromatic-Hs).

Analytical Data for Synthesis of HPC-Ibuprofen Conjugates, (Sample 2)

DS: 1.0 by acid base titration after saponification; 1.02 by ¹H-NMR spectroscopy; Yield: 2.4 g (76%); FTIR (KBr): 3263-3500 ν(OH), 1729 ν(CO_{Ester}), 1448 ν(CH₂) cm⁻¹; ¹H-NMR (DMSO-*d*₆, δ ppm): 1.02 (H-9), 0.84 (H-10), 1.32 (H-11), 1.76 (H-12), 2.41 (H-13), 3.15-4.39 (other AGU-H-1-5), 7.08-7.65 (aromatic-Hs).

Determination of Degree of Substitution (DS)

Sample (100 mg) was dissolved in 1M aq.NaOH (50 mL) and stirred overnight at room temperature. The pH of the mixture was adjusted to 7 by adding 0.01M HCl. Then a known amount of 1M aq.NaOH was added to the solution and back titrated using 0.1M HCl to reach the pH 7 again. The formula used for determination of DS is given below;

$$DS = [n.NaOH \times M(RU)] / [M_s - M_r(RCO) \times n.NaOH]$$

where, M(Ru) is molar mass of repeating unit of polymer, n.NaOH is the number of moles of

NaOH after saponification, $M_r(\text{RCO})$ is molar mass of ester functionality and M_s is mass of sample taken.

Determination of DS by $^1\text{H-NMR}$ Spectroscopy

The DS of the ibuprofen onto HPC was calculated from $^1\text{H-NMR}$ spectrum as per ref. [20] by the comparison of spectral intensities of signals.

Thermal Analysis and Degradation Kinetics

From TG curves, DTG was drawn and T_{di} , T_{dm} and T_{df} were calculated in order to compare the thermal stability of each step in conjugate, drug and polymer. Regarding the degradation kinetics, Friedman [21], Broido [22] and Chang [23] models were used. Friedman model determines the degradation kinetics as per eq. 1.

Order (n) of thermal degradation reaction was calculated from Chang model as per eq. 2. The plot of $\ln[(d\alpha/dt)/(1-\alpha)^n]$ versus $1/T$ gives a straight line. Energy of activation (E_a) and frequency factor (Z) were calculated from the slope of this straight line. The E_a and Z were also calculated from Broido kinetic model as per eq.3.

$$\ln\left(\frac{d\alpha}{dt}\right) = \ln Z + n \ln(1 - \alpha) - \frac{E_a}{RT} \quad \text{Eq. 1}$$

$$\ln\left[\frac{\frac{d\alpha}{dt}}{(1-\alpha)^n}\right] = \ln Z - \frac{E_a}{RT} \quad \text{Eq. 2}$$

$$\ln\left(\ln\frac{1}{y}\right) = -\frac{E_a}{RT} + \text{constant} \quad \text{Eq. 3}$$

where, in eq. 1-3, da/dt is the rate of weight loss directly taken from DTG curve; n is the reaction order; E_a is the activation energy; Z is the frequency factor of decomposition reaction; R is the gas constant; $1-\alpha$ is the weight of sample left at a certain temperature that is also taken from the TG curve; T is the absolute temperature recorded; w_0 is initial weight; w_∞ is final weight; $y = (w_t - w_\infty)/(w_0 - w_\infty)$ and w_t is weight at a given time t .

Shape index S of the DTG curve was used to calculate the reaction order n using Kissinger's method [24]. Rising and falling inflection points of the DTG curves were used to evaluate the shape index S using eq. 4. The value of n was calculated as a function of S value using eq. 5 and eq. 6.

$$S = (d^2 \alpha/dt^2)_L / (d^2 \alpha/dt^2)_R \quad \text{Eq. 4}$$

$$n = 1.88S (S \geq 0.45) \quad \text{Eq. 5}$$

$$n = 1.26S^{0.5} (S \leq 0.45) \quad \text{Eq. 6}$$

where, $d^2\alpha/dt^2$ is 2nd derivative of TG and its values are noted from 2DTG curve; R and L are the quantities at the right and left inflection points.

Conclusions

Chemically benign and facile organo-soluble HPC-Ibuprofen conjugates with high covalent drug loading are successfully synthesized under homogeneous reaction conditions. The synthesis protocols are monitored with various characterization techniques. These new HPC-Ibuprofen conjugates were found thermally more stable than pure ibuprofen. The DTG curve analysis indicated that maximum degradation temperature (T_{dm} 246°C) of HPC-Ibuprofen conjugates is higher than that of unmodified/pure ibuprofen (T_{dm} 233°C). Additionally, it is found that degradation rate of conjugate (12.3 %/min) is much lower than that of pure drug (143.6 %/min). These facts show that after conjugation, ibuprofen becomes more stable in the form of macromolecular prodrug, i.e., HPC-Ibuprofen conjugate. Therefore, these newly fabricated HPC-Ibuprofen conjugates could be useful prodrugs of ibuprofen for potential pharmaceutical and pharmacological applications.

Acknowledgements

K. Abbas gratefully acknowledges financial support provided by the Higher Education Commission (HEC), Pakistan under "HEC Indigenous 5000 fellowships Scheme".

References

1. S. R. Matkovic, G. M. Valle and L. E. Briand, *Latin American Applied Research*, **35**, 189 (2005).
2. E. Autret, R. J. Marty, B. Henry, C. Laborde, S. Courcier, J. M. Goehrs, G. Languillat and R. Launois, *European Journal of Clinical Pharmacology*, **51**, 367 (1997).
3. M. Sobczak, E. Witkowska, E. Olędzka and W. Kolodziejski, *Molecules*, **13**, 96 (2008).
4. M. A. Hussain, A. Zarish, K. Abbas, M. Sher, M. N. Tahir, W. Tremel, M. Amin, A. Ghafoor and B. A. Lodhi, *Cellulose*, **20**, 717 (2013).

5. E. Roseeuw, V. Coessens, A. M. Balazuc, M. Lagranderie, P. Chavarot, A. Pessina, M. Grazia, M. G. Neri, E. Schacht, G. Marchal and D. Domurado, *Antimicrobial Agents and Chemotherapy*, **4**, 3435 (2003).
6. M. C. Chung, E. I. Ferreira, J. L. Santos, J. Giarolla, D. G. Rando, A. E. Almeida, P. L. Bosquesi, R. F. Menegon and L. Blau, *Molecules*, **13**, 616 (2008).
7. S. Bashir, Z. Iqbal, M. Nisar and B. Ahmad, *Journal of the Chemical Society of Pakistan*, **25**, 192 (2003).
8. M. A. Hussain, *Journal of Polymer Science Part A: Polymer Chemistry*, **46**, 747 (2008).
9. J. Patrick, P. J. Sinko and A. N. Martin, *Martin's Physical Pharmacy and Pharmaceutical Science*, Lippincott Williams and Wilkins publishers, Ed. 5, 508 (2006).
10. F. Mira, P. Mariella and F. M. Winnik, *ACS Symposium Series*, **34**, 55 (2006).
11. H. Honarkar and M. Barikani, *Monatshefte fuer Chemie*, **140**, 1403 (2009).
12. K. Hoste, K. D. Winne and E. Schacht, *International Journal of Pharmaceutics*, **11**, 119 (2004).
13. M. A. Hussain, M. Badshah, M. S. Iqbal, M. N. Tahir, W. Tremel, S. V. Bhosale, M. Sher and M. T. Haseeb, *Journal of Polymer Science Part A: Polymer Chemistry*, **47**, 4202 (2009).
14. M. A. Hussain, K. Abbas, M. Sher, M. N. Tahir, W. Tremel, M. S. Iqbal, M. Amin and M. Badshah, *Macromolecular Research*, **19**, 1296 (2011).
15. M. A. Hussain, Z. Hassan, M. T. Haseeb, M. S. Iqbal, M. Sher, M. N. Tahir, T. Wolfgang, S. Bashir and R. Ahmed, *Pakistan Journal of Pharmaceutical Sciences*, **24**, 575 (2011).
16. M. A. Hussain and T. Heinze, *Polymer Bulletin*, **60**, 775 (2008).
17. M. A. Hussain, D. Shahwar, M. N. Hassan, M. N. Tahir, M. S. Iqbal and M. Sher, *Collection of the Czechoslovak. Chemical Communications*, **75**, 133 (2010).
18. M. A. Hussain, D. Shahwar, M. N. Tahir, M. Sher, M. N. Hassan and Z. Afzal, *Journal of the Serbian Chemical Society*, **75**, 165 (2010).
19. T. Liebert, M. A. Hussain, M. N. Tahir and T. Heinze, *Polymer Bulletin*, **57**, 857 (2008).
20. V. W. Goodlett, J. T. Dougherty and H. W. Patton, *Journal of Polymer Science Part A: Polymer Chemistry*, **9**, 155 (1971).
21. H. L. Friedman, *Journal of Polymer Science Part C: Polymer Symposia*, **6**, 183 (1964).
22. A. Broido, *Journal of Polymer Science Part A: Polymer Chemistry*, **7**, 1761 (1969).
23. W. L. Chang, *Journal of Applied Polymer Science*, **53**, 1759 (1994).
24. H. E. Kissinger, *Analytical Chemistry*, **29**, 1702 (1957).